ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype

Anne M. Minihane, Syrah Khan, Elizabeth C. Leigh-Firbank, Philippa Talmud, John W. Wright, Margaret C. Murphy, Bruce A. Griffin, Christine M. Williams

Research output: Contribution to journalArticlepeer-review

199 Citations (Scopus)


The study assessed the efficacy of fish oil supplementation in counteracting the classic dyslipidemia of the atherogenic lipoprotein phenotype (ALP). In addition, the impact of the common apolipoprotein E (apoE) polymorphism on the fasting and postprandial lipid profile and on responsiveness to the dietary intervention was established. Fifty-five ALP males (aged 34 to 69 years, body mass index 22 to 35 kg/m(2), triglyceride [TG] levels 1.5 to 4.0 mmol/L, high density lipoprotein cholesterol [HDL-C] 40% total LDL) completed a randomized placebo-controlled crossover trial of fish oil (3.0 g eicosapentaenoic acid/docosahexaenoic acid per day) and placebo (olive oil) capsules with the 6-week treatment arms separated by a 12-week washout period. In addition to fasting blood samples, at the end of each intervention arm, a postprandial assessment of lipid metabolism was carried out. Fish oil supplementation resulted in a reduction in fasting TG level of 35% (P
Original languageEnglish
Pages (from-to)1990-1997
Number of pages8
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Issue number8
Publication statusPublished - Aug 2000


  • Adult
  • Aged
  • Apolipoproteins E
  • Arteriosclerosis
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Cross-Over Studies
  • Double-Blind Method
  • Fasting
  • Fatty Acids, Nonesterified
  • Fish Oils
  • Food
  • Genotype
  • Humans
  • Lipoproteins
  • Male
  • Middle Aged
  • Phenotype
  • Placebos
  • Polymorphism, Genetic
  • Triglycerides

Cite this